- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- CADILA HEALTHCARE
CADILA HEALTHCARE Share Price 
(CADIL)
Here is the latest stock price and chart of Cadila Healthcare. For more details, see the Cadila Healthcare company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Feb 15, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)314.35 | Open (Rs) 318.00 | High (Rs) 319.00 | Low (Rs) 306.35 |
| % Change-1.47 | Volume 107,509 | Value (Rs) 33,509,801 | 52-Week H/L 432.40 / 306.35 |
| Live NSE Quotes | Feb 15, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)314.00 | Open (Rs) 317.80 | High (Rs) 319.00 | Low (Rs) 305.95 |
| % Change-1.41 | Volume 1,947,521 | Value (Rs) 606,675,706 | 52-Week H/L 432.50 / 305.95 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 19.16 | P/E Ratio (x) 16.40 | Market Cap (Rs m) 321,812.67 | P/BV (x) 3.68 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
CADILA HEALTHCARE Share Price Today:
CADILA HEALTHCARE last traded price was down 1.5% to Rs 314.4 on the BSE. On the NSE, CADILA HEALTHCARE last traded price was down 1.4% to Rs 314.0. The total volume of shares traded was 2.1 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 2.3%. And the benchmark S&P BSE SENSEX was at 35,809.0 (down 0.2%).
Over the last 30 days, the CADILA HEALTHCARE share price is down 11.5%. And over the last one year, CADILA HEALTHCARE share price is down 24.7%.
|
| |
Today's Market
Where Will the Two-Faced Market Go from Here?(Podcast)
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
Related Views On News
CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)
Aug 16, 2018 | Updated on Aug 16, 2018Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
Feb 4, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)
Feb 5, 2019A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)
Feb 5, 2019While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
MoreTRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE - ABBOTT INDIA COMPARISON
COMPARE CADILA HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.